Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs
about
The impact of comorbidity on cancer and its treatmentEffect of a structured, active, home-based cancer-treatment program for the management of patients on oral chemotherapyUnjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trialsA pilot study on the impact of known drug-drug interactions in cancer patientsDrug-drug interaction software in clinical practice: a systematic review.Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions.Developing Exposure/Response Models for Anticancer Drug Treatment: Special ConsiderationsPrevalence and nature of potential drug-drug interactions among kidney transplant patients in a German intensive care unit.Cytochrome P450 interactions are common and consequential in Massachusetts hospital discharges.Drug-drug interactions in pediatric oncology patients.Targeted cancer therapy: interactions with other medicines.High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.Drug-drug interactions in patients receiving tyrosine kinase inhibitors.Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis.Extreme doses of intravenous methadone for severe pain in two children with cancer.A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness.Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines.Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment.Drug-drug interactions in older patients with cancer: a report from the 15th Conference of the International Society of Geriatric Oncology, Prague, Czech Republic, November 2015.Assessment of drug therapy problems among patients with cervical cancer at Kenyatta National Hospital, Kenya.Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions.Solidified self-nanoemulsifying formulation for oral delivery of combinatorial therapeutic regimen: part I. Formulation development, statistical optimization, and in vitro characterization.Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.Drug-related deaths in hospital inpatients: A retrospective cohort study.What type and dose of antidepressants are cancer and non-cancer inpatients being prescribed: a retrospective case-control study at an Australian tertiary hospital.Potential Medication-Related Problems in Older Breast, Colon, and Lung Cancer Patients in the United States.Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently.To Take or Not to Take With Meals? Unraveling Issues Related to Food Effects Labeling for Oral Antineoplastic Drugs.Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer.Influence of aprepitant and localization of the patch on fentanyl exposure in patients with cancer using transdermal fentanyl.Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced Practitioner
P2860
Q26764935-47A11E90-0778-4CC9-A475-7FA9F230E071Q33831232-22BFD494-1B11-41FE-A77F-3E316073F14CQ34768999-90D64962-3E6E-4CAE-B5EC-209A9093E652Q35878347-6F83A70A-4710-4258-BB78-E785546C91EAQ35990349-B2512966-2471-4BF0-8EAE-A0F9A0D5D00BQ38295919-55724C9B-79D6-4070-A731-E6C72F751BD2Q38335110-7634A826-3A30-4024-BEF3-B82F8769A48CQ38557331-A1B6FBF8-F673-4BA3-9E77-A03F9154C4E2Q38617390-FAC63FFD-0E93-4BAD-AAE6-492DB70ED51BQ38684358-DF477CE5-69D5-4609-94B2-EC7C82E7AA49Q38756791-2E394702-2EC4-49B8-85F5-B6DBE3213457Q38817201-64B48B65-2D06-42DA-A4EA-CD9BBB643BD5Q38937142-430DEBF9-108B-48AC-A703-AF8B1F73E1C7Q39002032-CEC08331-1BE7-4F8C-AD6D-40349420D285Q39111080-A1220851-B1E0-49A9-9FF1-14270DFD2409Q39325947-6E979410-C5D0-45A7-8A1A-6FE3FD44E5A5Q41495525-B08B0F7B-03F2-49A2-A599-B2CE93E13B4AQ41605624-F07B8D15-D2A3-4804-93B1-48BCC0CA8160Q41683801-86613AF2-9017-4921-985C-7BABC9D152B1Q41962845-DCB27717-6887-44F5-BC97-B10327F9D733Q42019776-FA178C64-FC78-4E89-A998-18E057ECB7F8Q42672342-7CB7548D-ABBC-431B-BC07-153A5C67A462Q43557056-879A876F-FEC6-4F42-9600-4EF9CF67B547Q44575462-54CAB992-17EF-4787-8DD0-E4F74EFCB496Q47146166-AFC96E68-8F67-4666-A7BA-0129EE9D29AEQ47214402-C35FF907-C9FA-4D08-A3D7-92424C36C345Q47618017-14C6300E-BA81-484F-9EF7-C7B85BB86D67Q47914871-1D71470F-86B3-4556-9EEB-82FEFE5F71EEQ48159588-3735D0B1-779B-47C9-A331-A577218F8D2EQ49350350-938C9118-2BAA-4BE5-BA7B-1241388AFD12Q53074665-5741825D-3727-4604-831A-E934C4E7ED20Q53681128-104CF30A-C2EA-4C59-A814-B9AC9194EF59Q57498748-52E6942A-1905-4697-B4FF-87E6D243D63A
P2860
Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Prevalence of potential drug-d ...... ted with oral anticancer drugs
@en
type
label
Prevalence of potential drug-d ...... ted with oral anticancer drugs
@en
prefLabel
Prevalence of potential drug-d ...... ted with oral anticancer drugs
@en
P2093
P2860
P356
P1476
Prevalence of potential drug-d ...... ted with oral anticancer drugs
@en
P2093
D H S Brundel
D M Burger
F G A Jansman
R H J Mathijssen
R W F van Leeuwen
T van Gelder
P2860
P2888
P304
P356
10.1038/BJC.2013.48
P407
P577
2013-02-14T00:00:00Z
P5875
P6179
1002759960